Clinical trials: Tongue Neoplasms
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other…
- Conditions
- Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- NCT00588770
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 779 sites in United States, Puerto Rico and 1 more
- Volunteers
- 403 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy.
- Conditions
- Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm, Maxillary Sinus Carcinoma, Nasal Cavity Carcinoma
- Trial name
- NCT04870762
- Testing
- Best Practice, Medical Device Usage and Evaluation
- Where
- 7 sites in United States
- Volunteers
- 88 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- CARIO (NCT00963326)
- Testing
- laboratory biomarker analysis
- Where
- 9 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret
Bladder Cancer, Squamous Cell Carcinoma of the Lung
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have…
- Conditions
- Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
- Trial name
- NCT07217171
- Testing
- EVOLVE104
- Where
- 16 sites in United States
- Volunteers
- 160 people
- Sponsor
- EvolveImmune United, Inc
Tongue Carcinoma, Tongue Neoplasms
Submental Island Flap vs Radial Forearm Free Flap in Tongue Reconstruction
This study evaluates and compares the postoperative surgical outcomes and quality of life (QoL) in patients undergoing tongue reconstruction after tongue cancer resection, comparing two reconstructive options: the Submental…
- Conditions
- Tongue Carcinoma, Tongue Neoplasms, Quality of Life
- Trial name
- SIPF-RFFF (NCT07819617)
- Testing
- Submental Island Pedicled Flap (SIPF), Radial Forearm Free Flap (RFFF)
- Where
- Egypt
- Volunteers
- 28 people
- Sponsor
- Al-Azhar University
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer.
- Conditions
- Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma
- Trial name
- NCT04333537
- Testing
- Chest Radiography, Computed Tomography, Fludeoxyglucose F-18
- Where
- 107 sites in United States, Canada
- Volunteers
- 686 people
- Sponsor
- NRG Oncology
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive…
- Trial name
- NCT07552558
- Testing
- Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
This study is exploring the use of Panitumumab in Head and Neck Cancer. Panitumumab is an approved drug named Vectibix and is used as an anti-cancer agent in other cancers such as colorectal cancer.
- Conditions
- HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
- Trial name
- NCT06819228
- Testing
- Panitumumab IRDye 800
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Tongue Cancer
Anterolateral Thigh Myofascial Fat Composite Flap for Reconstruction of Hemiglossectomy Defects in Obese Patients With Tongue Cancer
Tongue cancer is a common malignant tumor in oral and maxillofacial surgery. After surgical resection, it is often accompanied by hemitongue defect.
- Trial name
- ALT-MF (NCT07682467)
- Testing
- The anterolateral femoral myofascial fat composite flap (ALT-MF) repairs tongue defects in patients with tongue cancer
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tongue Cancer
Normative Ranges of Lingual Strength and Endurance and the Impact of the IOPI Lingual Strength Trainer on Quantitative Functional Outcomes and Patient-Reported Outcomes After Partial Glossectomy or Hemiglossectomy for Oral Tongue Cancer, An Unblinded: Randomized Pilot Study
The purpose of this study is to learn more about tongue strength and endurance by using the Iowa Oral Performance Instrument (IOPI). The IOPI is a device that measures tongue pressure.
- Trial name
- NCT07124520
- Testing
- Iowa Oral Performance Instrument (IOPI)
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Mass Spectroscopy, Molecular Profile
Spectroscopic Analysis of Tongue Tumor Samples.
In squamous cell carcinoma of the tongue, complete surgical resection of the tumor generally represents the primary treatment strategy.
- Conditions
- Mass Spectroscopy, Molecular Profile, Surgical Margins, Squamous Cell Carcinoma
- Trial name
- SpecTum (NCT05104619)
- Testing
- tongue surgery
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Oral Tongue Squamous Cell Carcinoma
A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation.
- Trial name
- NCT06485778
- Testing
- Photon intensity modulated radiation therapy (IMRT), Life questionnaire's
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has…
- Conditions
- Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT02254278
- Testing
- Cisplatin, IMRT 6 weeks, IMRT 5 weeks
- Where
- 222 sites in United States, Canada and 2 more
- Volunteers
- 316 people
- Sponsor
- NRG Oncology
Tongue Cancer, Oral Cancer
Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
The goal of this clinical trial is to improve the surgical treatment of patients with oral cancer. We will explore whether the use of surgeon performed ultrasound during these surgeries result in better tumor removal.
- Conditions
- Tongue Cancer, Oral Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
- Trial name
- SURGIO (NCT07203911)
- Testing
- Ultrasound imaging, Standard Treatment
- Where
- 7 sites in United States, Denmark and 3 more
- Volunteers
- 150 people
- Sponsor
- Tobias Todsen
Tongue Neoplasms, Tongue Cancer
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality post-surgery.
- Conditions
- Tongue Neoplasms, Tongue Cancer, Oral Cancer
- Trial name
- PGSRT (NCT02584270)
- Testing
- Palatal Augmentation Prosthesis (PAP), Articulation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Cancer, Solid Malignant Tumors
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature…
- Conditions
- Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC
- Trial name
- NCT06915454
- Testing
- Intra-op PET/CT Specimen Scanner
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies the side effects and best dose of ipilimumab, nivolumab, and radiation therapy and how well they work in treating patients with advanced human papillomavirus (HPV) positive oropharyngeal squamous cell…
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Basaloid Carcinoma
- Trial name
- NCT03799445
- Testing
- Intensity-Modulated Radiation Therapy, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Oropharyngeal Cancers, HPV
Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy
The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy.
- Conditions
- Oropharyngeal Cancers, HPV, Tonsil Cancer, Base of Tongue Cancer
- Trial name
- Lombardi197 (NCT06902623)
- Testing
- Radiation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Georgetown University
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03737734
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.